Cresco Labs Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Cresco Labs heeft een totaal eigen vermogen van $365.4M en een totale schuld van $424.9M, wat de schuld-eigenvermogensverhouding op 116.3% brengt. De totale activa en totale passiva bedragen respectievelijk $1.4B en $1.0B. De EBIT Cresco Labs is $117.3M waardoor de rentedekking 2.1 is. Het heeft contanten en kortetermijnbeleggingen van $153.3M.

Belangrijke informatie

116.3%

Verhouding schuld/eigen vermogen

US$424.86m

Schuld

Rente dekkingsratio2.1x
ContantUS$153.30m
AandelenUS$365.37m
Totaal verplichtingenUS$1.02b
Totaal activaUS$1.38b

Recente financiële gezondheidsupdates

Recent updates

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Jan 04
Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

Is Cresco Labs (CSE:CL) Using Too Much Debt?

Sep 22
Is Cresco Labs (CSE:CL) Using Too Much Debt?

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Aug 11
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 33%

Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Jan 25
Cresco Labs (CSE:CL) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

Dec 13
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 24%?

We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Aug 22
We Think Cresco Labs (CSE:CL) Is Taking Some Risk With Its Debt

Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

May 23
Estimating The Intrinsic Value Of Cresco Labs Inc. (CSE:CL)

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $311.9M ) CL } overtreffen de korte termijn passiva ( $158.6M ).

Langlopende schulden: De kortetermijnactiva van CL ( $311.9M ) dekken de langetermijnschulden ( $859.0M ) niet.


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 74.3% ) CL wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van CL is de afgelopen 5 jaar gestegen van 0% naar 116.3%.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende CL voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: CL is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 30.1 % per jaar groeit.


Ontdek gezonde bedrijven